Results 171 to 180 of about 27,075 (224)

Potential Hepatoprotective Effects of Adenosine Triphosphate Against Olaparib-Induced Oxidative Liver Injury: An Experimental Rat Model. [PDF]

Drug Des Devel Ther
Baykan AR, Cerrah S, Kartal Baykan E, Tanas S, Yavuzer B, Yazici GN, Kuzucu M, Altuner D, Suleyman H.   +8 more
europepmc   +1 more source

Smyca-FOXM1 ribonucleoprotein complex promotes homologous recombination and tumor immune evasion to define a therapeutic target of triple-negative breast cancer. [PDF]

J Biomed Sci
Chen HH, Chang KH, Lee SR, Chiu CH, Yao BY, Carissa T, Hsu Hung SD, Kuo WL, Wang LH, Li CW, Hu CM, Chen HY, Chen RH.   +12 more
europepmc   +1 more source

Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis: A case report. [PDF]

Medicine (Baltimore)
Wang Y, Lin J, Zhang Y, Liang B, Lin X, Chen X, Guo L, Zhang Y, Chen Y, Zhang G.   +9 more
europepmc   +1 more source

ATP attenuates olaparib-induced gastric damage in rats. [PDF]

Front Pharmacol
Fakirullahoglu M, Temiz A, Yeni M, Sezgin ET, Yazici GN, Altuner D, Gulaboglu M, Suleyman H.   +7 more
europepmc   +1 more source

Phthalazine as a medically versatile polyheterocyclic core with underexplored anticancer potential. [PDF]

J Enzyme Inhib Med Chem
Biegański M, Matysiak J, Szeliga M.
europepmc   +1 more source

Targeting the DNA-repair chromatin-modifier protein SMYD3 as a novel epigenetics-based therapy for gastric cancer. [PDF]

J Exp Clin Cancer Res
De Marco K, Latrofa M, Forte G, Lepore Signorile M, Di Nicola E, Sanese P, Fasano C, Disciglio V, Candela E, Coletta S, Grossi V, Simone C.   +11 more
europepmc   +1 more source

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis. [PDF]

Front Oncol
Liang L, Yang B, Wu Y, Liu JL, Liu R, Sun L.   +5 more
europepmc   +1 more source

ROS-Induced DNA Damage Enhances Sensitivity to PARP Inhibition in HSC3 and SCC25 Head and Neck Squamous Cell Carcinoma Cell Lines. [PDF]

Curr Issues Mol Biol
Taghavi Pourianazar N.
europepmc   +1 more source

Covariate-adjusted AP-1 motif architecture and footprinting track olaparib-adaptive chromatin remodelling. [PDF]

Front Syst Biol
Dutta S.
europepmc   +1 more source

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy. [PDF]

J Immunother Cancer
Zhao Y, Wang Q, Xiao B, Jia J, Liu X, Ma S, Liu H, Zhou T, Yang Y, Fang W, Zhang L, Huang Y.   +11 more
europepmc   +1 more source